Janus Kinase 2-Dependent Activation of P38 Mitogen-activated Protein Kinase by Growth Hormone
Tao Zhu,Peter E. Lobie
DOI: https://doi.org/10.1074/jbc.275.3.2103
IF: 5.485
2000-01-01
Journal of Biological Chemistry
Abstract:We demonstrate here that p38 mitogen-activated protein (MAP) kinase is activated in response to cellular stimulation by human GH (hGH) in Chinese hamster ovary cells stably transfected with GH receptor cDNA. This activation requires the proline-rich box 1 region of the GH receptor required for JAK2 association and is prevented by pretreatment of cells with the JAK2-specific inhibitor AG490. ATF-2 is both phosphorylated and transcriptionally activated by hGH, and its transcriptional activation also requires the proline-rich box 1 region of the GH receptor. Expression of wild type JAK2 can further enhance hGH-induced ATF-2-, CHOP-, and Elk-1-mediated transcriptional activation, whereas pretreatment with AG490 is inhibitory. Use of either specific pharmacological inhibitors or transient transfection of cells with p38α MAP kinase cDNA or a dominant negative variant demonstrated that hGH-stimulated transcriptional activation of ATF-2 and CHOP, but not Elk-1, is regulated by p38 MAP kinase. Both the p38 MAP kinase and p44/42 MAP kinase are critical for hGH-stimulated mitogenesis, whereas only p38 MAP kinase is required for hGH-induced actin cytoskeletal re-organization. p38 MAP kinase is therefore an important regulator in coordinating the pleiotropic effects of GH. We demonstrate here that p38 mitogen-activated protein (MAP) kinase is activated in response to cellular stimulation by human GH (hGH) in Chinese hamster ovary cells stably transfected with GH receptor cDNA. This activation requires the proline-rich box 1 region of the GH receptor required for JAK2 association and is prevented by pretreatment of cells with the JAK2-specific inhibitor AG490. ATF-2 is both phosphorylated and transcriptionally activated by hGH, and its transcriptional activation also requires the proline-rich box 1 region of the GH receptor. Expression of wild type JAK2 can further enhance hGH-induced ATF-2-, CHOP-, and Elk-1-mediated transcriptional activation, whereas pretreatment with AG490 is inhibitory. Use of either specific pharmacological inhibitors or transient transfection of cells with p38α MAP kinase cDNA or a dominant negative variant demonstrated that hGH-stimulated transcriptional activation of ATF-2 and CHOP, but not Elk-1, is regulated by p38 MAP kinase. Both the p38 MAP kinase and p44/42 MAP kinase are critical for hGH-stimulated mitogenesis, whereas only p38 MAP kinase is required for hGH-induced actin cytoskeletal re-organization. p38 MAP kinase is therefore an important regulator in coordinating the pleiotropic effects of GH. growth hormone human GH mitogen-activated protein MAP kinase Chinese hamster ovary c-Jun amino-terminal kinases stress-activated protein kinase MAPK/extracellular signal-regulated kinase kinase activating transcription factor-2 N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate phosphate-buffered saline tetramethylrhodamine isothiocyanate Growth hormone (GH),1 as the major regulator of postnatal body growth, possesses diverse and pleiotropic effects on the growth, differentiation, and metabolism of cells (1.Carter-Su C. Smit L.S. Recent Prog. Horm. Res. 1998; 53: 61-82PubMed Google Scholar, 2.Lobie P.E. Bengtsson B.A. Growth Hormone. Kluwer Academic Publishers, Norwell, MA1999: 17-35Google Scholar). The GH receptor is a single membrane-spanning glycoprotein in the cytokine receptor superfamily (3.Hibi M. Hirano T. Int. Rev. Immunol. 1998; 17: 75-102Crossref PubMed Google Scholar) that consists of a ligand-binding external domain and a 350-amino acid residue cytoplasmic domain required for intracellular signal transduction (1.Carter-Su C. Smit L.S. Recent Prog. Horm. Res. 1998; 53: 61-82PubMed Google Scholar,2.Lobie P.E. Bengtsson B.A. Growth Hormone. Kluwer Academic Publishers, Norwell, MA1999: 17-35Google Scholar). GH receptor signaling involves ligand-induced receptor homodimerization and activation of the tyrosine kinase JAK2 by association with the GH receptor (1.Carter-Su C. Smit L.S. Recent Prog. Horm. Res. 1998; 53: 61-82PubMed Google Scholar, 2.Lobie P.E. Bengtsson B.A. Growth Hormone. Kluwer Academic Publishers, Norwell, MA1999: 17-35Google Scholar, 4.Argetsinger L.S. Campbell G.S. Yang X. Witthuhn B.A. Silvennoinen O. Ihle J.N. Carter-Su C. Cell. 1993; 74: 237-244Abstract Full Text PDF PubMed Scopus (797) Google Scholar). The proline-rich Box1 motif of the receptor has been identified as the site of association with JAK2. Multiple effector molecules downstream of JAK2-mediating GH signal transduction have now been identified (5.Winston L.A. Hunter T. J. Biol. Chem. 1995; 270: 30837-30840Abstract Full Text Full Text PDF PubMed Scopus (155) Google Scholar, 6.Yamauchi T. Kaburagi Y. Ueki K. Tsuji Y. Stark G.R. Kerr I.M. Tsushima T. Akanuma Y. Komuro I. Tobe K. Yazaki Y. Kadowaki T. J. Biol. Chem. 1998; 273: 15719-15726Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar, 7.Ridderstrale M. Degerman E. Tornqvist H. J. Biol. Chem. 1995; 270: 3471-3474Abstract Full Text Full Text PDF PubMed Scopus (124) Google Scholar, 8.VanderKuur J. Allevato G. Billestrup N. Norstedt G. Carter-Su C. J. Biol. Chem. 1995; 270: 7587-7593Abstract Full Text Full Text PDF PubMed Scopus (128) Google Scholar, 9.Rui L. Mathews L.S. Hotta K. Gustafson T.A. Carter-Su C. Mol. Cell. Biol. 1997; 17: 6633-6644Crossref PubMed Google Scholar, 10.Ram P.A. Waxman D.J. J. Biol. Chem. 1997; 272: 17694-17702Abstract Full Text Full Text PDF PubMed Scopus (153) Google Scholar, 11.Kim S.O. Jiang J. Yi W. Feng G.S. Frank S.J. J. Biol. Chem. 1998; 273: 2344-2354Abstract Full Text Full Text PDF PubMed Scopus (134) Google Scholar). We have also recently demonstrated that GH stimulates the formation of a multiprotein signaling complex centered around p125FAK (12.Zhu T. Goh E.L.K. Lobie P.E. J. Biol. Chem. 1998; 273: 10682-10689Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar) and p130Cas-CrkII (13.Zhu T. Goh E.L.K. LeRoith D. Lobie P.E. J. Biol. Chem. 1998; 273: 33864-33875Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar) leading to JNK/SAPK activation. The mitogen-activated protein kinase (MAPK) superfamily, encompassing p44/42 MAP kinase, c-Jun amino-terminal kinases (JNK), and p38 MAP kinase, are proline-directed serine-threonine protein kinases that have important functions as mediators of cellular responses to a variety of extracellular stimuli (14.Garrington T.P. Johnson G.L. Curr. Opin. Cell Biol. 1999; 11: 211-218Crossref PubMed Scopus (1099) Google Scholar, 15.Vojtek A.B. Der C.J. J. Biol. Chem. 1998; 273: 19925-19928Abstract Full Text Full Text PDF PubMed Scopus (481) Google Scholar). p44/42 MAP kinase has been implicated in mitogenic growth in a variety of cell contexts, and its activation is via a well known sequential cascade involving SHC, Grb2, son-of-sevenless, Ras, Raf, and MAP/extracellular signal-regulated kinase (MEK) (14.Garrington T.P. Johnson G.L. Curr. Opin. Cell Biol. 1999; 11: 211-218Crossref PubMed Scopus (1099) Google Scholar, 15.Vojtek A.B. Der C.J. J. Biol. Chem. 1998; 273: 19925-19928Abstract Full Text Full Text PDF PubMed Scopus (481) Google Scholar). The p38 MAP kinases have been shown to be activated by a series of cytokines, growth factors, and autonomic neurotransmitters (16.Foltz I.N. Lee J.C. Young P.R. Schrader J.W. J. Biol. Chem. 1997; 272: 3296-3301Abstract Full Text Full Text PDF PubMed Scopus (154) Google Scholar, 17.Hedges J.C. Yamboliev I.A. Ngo M. Horowitz B. Adam L.P. Gerthoffer W.T. Am. J. Physiol. 1998; 275: C527-C534Crossref PubMed Google Scholar, 18.Rousseau S. Houle F. Landry J. Huot J. Oncogene. 1997; 15: 2169-2177Crossref PubMed Google Scholar, 19.Rausch O. Marshall C.J. J. Biol. Chem. 1999; 274: 4096-4105Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar) in addition to the stress and pro-inflammatory signals (20.Han J. Lee J.-D. Bibbs L. Ulevitch R.J. Science. 1994; 265: 808-811Crossref PubMed Google Scholar, 21.Lee J.C. Laydon J.T. McDonnell P.C. Gallagher T.F. Kumar S. Green D. McNulty D. Blumenthal M.J. Heyes R.J. Landvatter S.W. Strickler J.E. McLaughlin M.M. Siemens I. Fisher S. Livi G.P. White J.R. Adams J.L. Young P.R. Nature. 1994; 372: 739-746Crossref PubMed Google Scholar, 22.Rouse J. Cohen P. Trigon S. Morange M. Alonso-Llamazares A. Zamanillo D. Hunt T. Nebreda A.R. Cell. 1994; 78: 1027-1037Abstract Full Text PDF PubMed Scopus (1464) Google Scholar). Activation of p38 MAP kinase involves phosphorylation on threonine and tyrosine residues present in a TGY amino acid motif (23.Raingeaud J. Gupta S. Rogers J.S. Dickens M. Han J. Ulevitch R.J. Davis R.J. J. Biol. Chem. 1995; 270: 7420-7426Abstract Full Text Full Text PDF PubMed Scopus (1992) Google Scholar, 24.Doza Y.N. Cuenda A. Thomas G.M. Cohen P. Nebreda A.R. FEBS Lett. 1995; 364: 223-228Crossref PubMed Scopus (69) Google Scholar), resulting in increased enzyme activity (25.Han J. Lee J.D. Bibbs L. Ulevitch R.J. Science. 1994; 265: 808-811Crossref PubMed Google Scholar, 26.Jiang Y. Chen C. Li Z. Guo W. Gegner J.A. Lin S. Han J. J. Biol. Chem. 1996; 271: 17920-17926Abstract Full Text Full Text PDF PubMed Scopus (643) Google Scholar). At least four isoforms of p38 MAP kinase have been described (20.Han J. Lee J.-D. Bibbs L. Ulevitch R.J. Science. 1994; 265: 808-811Crossref PubMed Google Scholar, 21.Lee J.C. Laydon J.T. McDonnell P.C. Gallagher T.F. Kumar S. Green D. McNulty D. Blumenthal M.J. Heyes R.J. Landvatter S.W. Strickler J.E. McLaughlin M.M. Siemens I. Fisher S. Livi G.P. White J.R. Adams J.L. Young P.R. Nature. 1994; 372: 739-746Crossref PubMed Google Scholar, 22.Rouse J. Cohen P. Trigon S. Morange M. Alonso-Llamazares A. Zamanillo D. Hunt T. Nebreda A.R. Cell. 1994; 78: 1027-1037Abstract Full Text PDF PubMed Scopus (1464) Google Scholar, 26.Jiang Y. Chen C. Li Z. Guo W. Gegner J.A. Lin S. Han J. J. Biol. Chem. 1996; 271: 17920-17926Abstract Full Text Full Text PDF PubMed Scopus (643) Google Scholar, 27.Kumar S. McDonnell P.C. Gum R.J. Hand A.T. Lee J.C. Young P.R. Biochem. Biophys. Res. Commun. 1997; 255: 533-538Crossref Scopus (438) Google Scholar, 28.Lechner C. Zahalka M.A. Giot J.-F. Moller N.P.H. Ullrich A. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 4355-4359Crossref PubMed Scopus (268) Google Scholar, 29.Li Z. Jiang Y. Ulevitch R.J. Han J. Biochim. Biophys. Acta. 1996; 228: 334-340Google Scholar, 30.Cuenda A. Cohen P. Buee-Scherrer V. Goedert M. EMBO J. 1997; 16 (220): 295Crossref PubMed Scopus (308) Google Scholar). Experiments with dominant-negative or active mutant proteins have demonstrated that p38 MAP kinase lies downstream of Rac, Cdc42, GCK, PAK1, TAK1, ASK1, TPL1, and RAFTK/PYK2 (31.Fanger G.R. Gerwins P. Widmann C. Jarpe M.B. Johnson G.L. Curr. Opin. Genet. & Dev. 1997; 7: 67-74Crossref PubMed Scopus (286) Google Scholar, 32.Minden A. Lin A. Claret F.-X. Abo A. Karin M. Cell. 1995; 81: 1147-1157Abstract Full Text PDF PubMed Scopus (1419) Google Scholar, 33.Zhang S. Han J. Sells M.A. Chernoff J. Knaus U.G. Ulevitch R.J. Bokoch G.M. J. Biol. Chem. 1995; 270: 23934-23936Abstract Full Text Full Text PDF PubMed Scopus (644) Google Scholar, 34.Bagrodia S. Derijard B. Davis R.J. Cerione R.A. J. Biol. Chem. 1995; 270: 27995-27998Abstract Full Text Full Text PDF PubMed Scopus (589) Google Scholar, 35.Yuasa T. Ohno S. Kehrl J.H. Kyriakis J.M. J. Biol. Chem. 1998; 273: 22681-22692Abstract Full Text Full Text PDF PubMed Scopus (235) Google Scholar, 36.Moriguchi T. Kuroyanagi N. Yamaguchi K. Gotoh Y. Irie K. Kano T. Shirakabe K. Muro Y. Shibuya H. Matsumoto K. Nishida E. Hagiwara M. J. Biol. Chem. 1996; 271: 13675-13679Abstract Full Text Full Text PDF PubMed Scopus (400) Google Scholar, 37.Ichijo H. Nishida E. Irie K. ten Dijke P. Saitoh M. Moriguchi T. Takagi M. Matsumoto K. Miyazono K. Gotoh Y. Science. 1997; 275: 90-94Crossref PubMed Scopus (1913) Google Scholar, 38.Kim S.O. Irwin P. Katz S. Pelech S.L. J. Cell. Biochem. 1998; 71: 286-301Crossref PubMed Scopus (20) Google Scholar, 39.Pandey P. Avraham S. Kumar S. Nakazawa A. Place A. Ghanem L. Rana A. Kumar V. Majumder P.K. Avraham H. Davis R.J. Kharbanda S. J. Biol. Chem. 1999; 274: 10140-10144Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar) and is directly activated by three dual-specificity MAPK kinases, MKK3, MKK4, and MKK6 (36.Moriguchi T. Kuroyanagi N. Yamaguchi K. Gotoh Y. Irie K. Kano T. Shirakabe K. Muro Y. Shibuya H. Matsumoto K. Nishida E. Hagiwara M. J. Biol. Chem. 1996; 271: 13675-13679Abstract Full Text Full Text PDF PubMed Scopus (400) Google Scholar, 40.Dérijard B. Raingeaud J. Barret T. Wu I.-H. Han J. Ulevitch R.J. Davis R.J. Science. 1995; 267: 683-685Crossref Scopus (1370) Google Scholar, 41.Han J. Lee J.-D. Jiang Y. Li Z. Feng L. Ulevitch R.J. J. Biol. Chem. 1996; 271: 2886-2891Abstract Full Text Full Text PDF PubMed Scopus (476) Google Scholar, 42.Raingeaud J. Whitmarsh A.J. Barret T. Dérijard B. Davis R.J. Mol. Cell. Biol. 1996; 16: 1247-1255Crossref PubMed Google Scholar, 43.Stein B. Brady H. Yang M.X. Young D.B. Barbosa R.J. J. Biol. Chem. 1996; 271: 11427-11433Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar). Some of the substrates for p38 MAP kinase that may be physiologically relevant have been identified. These include the transcription factors ATF-2 (23.Raingeaud J. Gupta S. Rogers J.S. Dickens M. Han J. Ulevitch R.J. Davis R.J. J. Biol. Chem. 1995; 270: 7420-7426Abstract Full Text Full Text PDF PubMed Scopus (1992) Google Scholar, 42.Raingeaud J. Whitmarsh A.J. Barret T. Dérijard B. Davis R.J. Mol. Cell. Biol. 1996; 16: 1247-1255Crossref PubMed Google Scholar), CHOP (44.Wang X.Z. Ron R. Science. 1996; 272: 1347-1349Crossref PubMed Google Scholar), Elk-1 (45.Whitmarsh A.J. Yang S.-H. Su M.S.-S. Sharrocks A.D. Davis R.J. Mol. Cell. Biol. 1997; 17: 2360-2371Crossref PubMed Google Scholar, 46.Price M.A. Cruzalegui F.H. Treisman R. EMBO J. 1996; 15: 6552-6563Crossref PubMed Scopus (297) Google Scholar), CREB, ATF-1 (47.Iordanov M. Bender K. Ade T. Schmid W. Sachsenmaier C. Engel K. Gaestel M. Rahmsdorf H.J. Herrlich P. EMBO J. 1997; 16: 1009-1022Crossref PubMed Scopus (193) Google Scholar, 48.Pierrat B. da Silva Correia J. Mary J.L. Tomas-Zuber M. Lesslauer W. J. Biol. Chem. 1998; 273: 29661-29671Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar), Sap1a (45.Whitmarsh A.J. Yang S.-H. Su M.S.-S. Sharrocks A.D. Davis R.J. Mol. Cell. Biol. 1997; 17: 2360-2371Crossref PubMed Google Scholar, 46.Price M.A. Cruzalegui F.H. Treisman R. EMBO J. 1996; 15: 6552-6563Crossref PubMed Scopus (297) Google Scholar), MEF2C, and MEF-2A (49.Han J. Jiang Y. Li Z. Kravchenko V.V. Ulevitch R.J. Nature. 1997; 386: 296-299Crossref PubMed Scopus (656) Google Scholar, 50.Zetser A. Gredinger E. Bengal E. J. Biol. Chem. 1999; 274: 5193-5200Abstract Full Text Full Text PDF PubMed Scopus (370) Google Scholar, 51.Yang S.H. Galanis A. Sharrocks A.D. Mol. Cell. Biol. 1999; 19: 4028-4038Crossref PubMed Scopus (215) Google Scholar), which can be phosphorylated and transcriptionally activated by p38 MAP kinase. p38 MAP kinase also activates the following downstream protein kinases: MAPKAP kinase-2, MAPKAP kinase-3, and p38-regulated/activated protein kinase (22.Rouse J. Cohen P. Trigon S. Morange M. Alonso-Llamazares A. Zamanillo D. Hunt T. Nebreda A.R. Cell. 1994; 78: 1027-1037Abstract Full Text PDF PubMed Scopus (1464) Google Scholar, 52.New L. Jiang Y. Zhao M. Liu K. Zhu W. Flood L.J. Kato Y. Parry G.C. Han J. EMBO J. 1998; 17: 3372-3384Crossref PubMed Scopus (263) Google Scholar, 53.McLaughlin M.M. Kumar S. McDonnell P.C. Van Horn S. Lee J.C. Livi G.P. Young P.R. J. Biol. Chem. 1996; 271: 8488-8492Abstract Full Text Full Text PDF PubMed Scopus (299) Google Scholar). We and others (54.Möller C. Hansson A. Enberg B. Lobie P.E. Norstedt G. J. Biol. Chem. 1992; 267: 23403-23408Abstract Full Text PDF PubMed Google Scholar, 55.Campbell G.S. Pang L. Miyasaka T. Saltiel A.R. Carter-Su C. J. Biol. Chem. 1992; 267: 6074-6080Abstract Full Text PDF PubMed Google Scholar, 56.Harding P.A. Wang X.Z. Kopchick J.J. Receptor. 1995; 5: 81-92PubMed Google Scholar) have previously demonstrated GH activation of both p44/42 MAP kinase and c-Jun amino-terminal kinase (JNK/SAPK1) (13.Zhu T. Goh E.L.K. LeRoith D. Lobie P.E. J. Biol. Chem. 1998; 273: 33864-33875Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar). We demonstrate here that hGH transiently phosphorylates and activates p38 MAP kinase in CHO cell lines stably transfected with rat GH receptor cDNA and that the activation of the p38 MAP kinase pathway by hGH is JAK2-dependent. Furthermore, both ATF-2 and CHOP (GADD153) are transcriptionally activated by hGH in a JAK2-dependent manner, and p38 MAP kinase is required for both cytoskeletal re-organization and cell proliferation stimulated by hGH. The p38 MAP kinase pathway is therefore an important regulator of the pleiotropic effects of GH. Recombinant human growth hormone (hGH) was a generous gift of Novo-Nordisk (Singapore). The JAK2 inhibitor tyrphostin AG490, MEK1 inhibitor PD98059, and the p38 MAP kinase inhibitor SB203580 were purchased from Calbiochem. Protein A/G plus agarose was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The enhanced chemiluminescence (ECL) kit was purchased from Amersham Pharmacia Biotech. The immobilized phospho-p38 MAP kinase (Thr-180/Tyr-182) monoclonal antibody, immobilized phospho-p44/42 MAP kinase (Thr-202/Tyr-204) monoclonal antibody, phospho-p38 MAP kinase (Thr-180/Tyr-182) polyclonal antibody, phospho-ATF-2 (Thr-71) polyclonal antibody, ATF-2 polyclonal antibody, phospho-Elk-1 (Ser-383) polyclonal antibody, Elk-1 polyclonal antibody, and Elk-1 fusion protein were purchased from New England Biolabs (Beverly, MA). The glutathione S-transferase fusion protein of the amino-terminal portion of activating transcription factor-2 (ATF-2) (base pairs 1–109) was a generous gift of Dr. Shengcai Lin (Institute of Molecular and Cell Biology, Singapore). Transfection reagent DOTAP was purchased from Roche Molecular Biochemicals. [3H]Thymidine was purchased from Amersham Pharmacia Biotech. All other reagents were purchased from Sigma. The wild type JAK2 expression plasmid has been described previously (57.Lobie P.E. Ronsin B. Silvennoinen O. Haldosen L.A. Norstedt G. Morel G. Endocrinology. 1996; 137: 4037-4045Crossref PubMed Scopus (64) Google Scholar). The fusion trans-activator plasmids (pFA-ATF-2, pFA-CHOP, and pFA2-Elk-1) consisting of the DNA binding domain of Gal4 (residue 1–147) and the trans-activation domain of ATF-2, CHOP, or Elk-1 were purchased from Stratagene (La Jolla, CA). pFC2-dbd plasmid is the negative control for the pFA plasmid to ensure the observed effects are not due to the Gal4 DNA binding domain and was also obtained from Stratagene. Wild type or p38α MAP kinase dominant negative (TGY-AGF) mutant and wild type p42 MAP kinase in pcDNA3 expression vector were kindly provided by Dr. Jiahua Han (San Diego, CA). SPI-GLE1-Luc plasmid has been previously described (58.Wood T.J. Sliva D. Lobie P.E. Goullieux F. Mui A.L. Groner B. Norstedt G. Haldosen L.A. Mol. Cell. Endocrinol. 1997; 130: 69-81Crossref PubMed Scopus (44) Google Scholar). All plasmids were prepared with the plasmid megaprep kit from Qiagen (Hilden, Germany). Rat GH receptor cDNAs were cloned into an expression plasmid containing an SV40 enhancer and a human metallothionein IIa promoter. The cDNAs were transfected into CHO-K1 cells using Lipofectin together with the pIPB-1 plasmid, which contains a neomycin resistance gene fused to the thymidine kinase promoter. Stable integrants were selected using 1000 mg/ml G418. The complete rat GH receptor cDNA coding for amino acids 1–638 was expressed in CHO4–638 or CHOA-638 cells and will be referred to as CHO-GHR1–638 (54.Möller C. Hansson A. Enberg B. Lobie P.E. Norstedt G. J. Biol. Chem. 1992; 267: 23403-23408Abstract Full Text PDF PubMed Google Scholar). The construction of GH receptor cDNA expression plasmids containing a deletion of box 1 (Δ297–311) and the individual substitution of proline residues 300, 301, 303, and 305 in box 1 for alanine has been described previously (59.VanderKuur J.A. Wang X. Zhang L. Campbell G.S. Allevato G. Billestrup N. Norstedt G. Carter-Su C. J. Biol. Chem. 1994; 269: 21709-21717Abstract Full Text PDF PubMed Google Scholar). These cDNAs were stably transfected into CHO-K1 cells; the Δ297–311 mutation was expressed in CHO-GHR1–638Δ297–311 cells, and P300A,P301A,P303A,P305A was expressed in CHO-GHR1–638P300,301,303,305A cells (cells were a kind gift of Dr. Nils Billestrup) (59.VanderKuur J.A. Wang X. Zhang L. Campbell G.S. Allevato G. Billestrup N. Norstedt G. Carter-Su C. J. Biol. Chem. 1994; 269: 21709-21717Abstract Full Text PDF PubMed Google Scholar). The level of receptor expression for the individual cell clones is comparable between clones and has been described previously (54.Möller C. Hansson A. Enberg B. Lobie P.E. Norstedt G. J. Biol. Chem. 1992; 267: 23403-23408Abstract Full Text PDF PubMed Google Scholar, 59.VanderKuur J.A. Wang X. Zhang L. Campbell G.S. Allevato G. Billestrup N. Norstedt G. Carter-Su C. J. Biol. Chem. 1994; 269: 21709-21717Abstract Full Text PDF PubMed Google Scholar). CHO-GHR1–638,CHO-GHR1–638Δ297–311, and CHO-GHR1–638P300,301,303,305A were maintained in Ham's F-12 medium (F-12) plus 10% v/v fetal calf serum, 100 units/ml penicillin, and 100 mg/ml streptomycin in a humidified atmosphere containing 5% CO2 and 95% air at 37 °C as described previously (59.VanderKuur J.A. Wang X. Zhang L. Campbell G.S. Allevato G. Billestrup N. Norstedt G. Carter-Su C. J. Biol. Chem. 1994; 269: 21709-21717Abstract Full Text PDF PubMed Google Scholar). Prior to treatment, cells were deprived of serum for 12–16 h in Ham's F-12 medium. Unless otherwise indicated, the final concentration of the MEK1 inhibitor PD98059 was 30 μm, p38 MAP kinase inhibitor SB205380 was 10 μm, and hGH was 50 nm. This concentration of GH is within the physiological range for circulating rodent GH (60.Tannenbaum G.S. Martin J.B. Endocrinology. 1976; 98: 562-570Crossref PubMed Google Scholar, 61.Eden S. Schwartz J. Kostyo J.L. Endocrinology. 1982; 111: 1505-1512Crossref PubMed Google Scholar). Immunoblotting for p38 MAP kinase, dual phospho-p38 MAP kinase, Elk-1, phospho-Elk-1, ATF-2, and phospho-ATF-2 were carried out as described previously (12.Zhu T. Goh E.L.K. Lobie P.E. J. Biol. Chem. 1998; 273: 10682-10689Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar, 13.Zhu T. Goh E.L.K. LeRoith D. Lobie P.E. J. Biol. Chem. 1998; 273: 33864-33875Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar). After preincubation with inhibitors for respective time and/or incubation with hGH for the appropriate duration, the cells were washed twice with ice-cold PBS, and cells were lysed at 4 °C in 1 ml of lysis buffer (50 mm Tris-HCl, pH 7.4, 1% Triton-100, 150 mmNaCl, 1 mm EGTA, 1 mm EDTA, 0.2 mmsodium orthovanadate, 0.5% Nonidet P-40, 0.1% phenylmethylsulfonyl fluoride, 10 μg/ml each aprotinin and leupeptin) for 30 min with regular vortices. Cell lysates were centrifuged at 14,000 ×g for 15 min, and the resulting supernatants were collected, and protein concentration was determined. Cell lysates dissolved in 1× SDS-polyacrylamide gel electrophoresis sample buffer containing 25 mm Tris-HCl, pH 6.8, 1% SDS, 1% mercaptoethanol, and bromphenol blue, boiled for 10 min, and centrifuged at 14,000 ×g for 2 min were analyzed on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were blocked with 5% non-fat dry milk in phosphate-buffered saline with 0.1% Tween 20 (PBST) for 1 h at 22 °C. The blots were then treated with the primary antibody in PBST containing 1% non-fat dry milk at 4 °C overnight. After three washes with PBST, immunolabeling was detected by ECL according to the manufacturer's instructions. Membranes were then stripped by incubation for 30 min at 50 °C in a solution containing 62.5 mm Tris-HCl, pH 6.7, 2% SDS, and 0.7% mercaptoethanol. Blots were then washed for 30 min with several changes of PBST at room temperature. Efficacy of stripping was determined by re-exposure of the membranes to ECL. Thereafter, blots were reblocked and immunolabeled as described above. p38 MAP kinase assays were performed using New England Biolabs assay kit specific for p38α and p38β MAP kinase according to the manufacturer's instructions. In brief, CHO-GHR1–638 cells were serum-deprived for 16 h, treated with 50 nm hGH, and the cells lysed at 4 °C in 1 ml of lysis buffer (20 mm Tris-HCl, pH 7.4, 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1% Triton X-100, 2.5 mm sodium pyrophosphate, 1 mmglycerol phosphate, 1 mm Na3VO4, 0.1% phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin) per sample. The lysates were centrifuged at 15,000 × g for 15 min at 4 °C. The supernatant containing 300 μg of protein per sample was incubated overnight at 4 °C with 20 μl of immobilized phospho-p38 MAP kinase (Thr-180/Tyr-182) monoclonal antibody in a final volume of 500 μl in 1× lysis buffer. The bead slurries were washed twice with 500 μl of lysis buffer containing 0.1% phenylmethylsulfonyl fluoride and twice with 500 μl of kinase buffer (25 mm Tris-HCl, pH 7.5, 5 mm glycerol phosphate, 2 mmdithiothreitol, 0.1 mm Na3VO4, 10 mm MgCl2). 3 μg of recombinant glutathioneS-transferase-ATF2 protein containing 1–109 amino-terminal amino acids of ATF-2 was added to each sample. The kinase reactions were carried out in the presence of 100 mm ATP at 30 °C for 30 min. Phosphorylation of ATF-2 at Thr-71 was determined by Western blot using phospho-ATF-2 (Thr-71) antibody (1:1000). p44/42 MAP kinase assays were also performed using New England Biolabs assay kit according to the manufacturer's instructions. In brief, cells were serum-deprived for 16 h, treated with 50 nm hGH, and lysed at 4 °C in 1 ml of lysis buffer (as described above) per sample. The lysates were centrifuged at 15,000 × g for 15 min at 4 °C. The supernatant containing 200 μg of protein per sample was incubated overnight at 4 °C with 15 μl of immobilized phospho-specific p44/42 MAP kinase (Thr-202/Tyr-204) monoclonal antibody in a final volume of 500 μl in 1× lysis buffer. The pellets were washed twice with 500 μl of lysis buffer containing 0.1% phenylmethylsulfonyl fluoride and washed twice with 500 μl of kinase buffer (25 mm Tris-HCl, pH 7.5, 5 mm glycerol phosphate, 2 mm dithiothreitol, 0.1 mmNa3VO4, 10 mm MgCl2). The kinase reactions were performed in the presence of 2 μg of Elk-1 fusion protein and 200 μm ATP at 30 °C for 30 min. Elk-1 phosphorylation was selectively detected by western immunoblotting using a chemiluminescent detection system and a specific phospho-Elk-1 (Ser-383) antibody (1:1000). CHO-GHR1–638 cells were cultured to 60–80% confluence for transfection experiments in 6-well plates. 1 μg of reporter plasmid pFR-Luc was transfected together with 20 ng of the respective fusion trans-activator plasmid (pFA-ATF-2, pFA-CHOP, pFA-Elk-1, or pFC2-dbd). For transient transfection of MAP kinases, either 1.5 μg of pCDNA3-p38α MAPK, dominant negative pCDNA3-p38α MAPK, or pCDNA3-p42 MAPK were transfected in each well. Control empty vector was used to normalize the amount of plasmids in each well. For each well, 4 μg of DOTAP for each μg of DNA was used as per the manufacturer's instructions. DNA and the DOTAP reagents were diluted separately in 100 μl of serum-free medium mixed and incubated at room temperature for 30 min. DNA-lipid complex was diluted to a final volume of 6 ml (for triplicate samples) with serum-free medium. Cells in each well were rinsed once with 2 ml of serum-free medium, and 2 ml of diluted DNA-lipid complex was overlaid in each well and incubated for 6 h. After incubation, complete Ham's F-12 medium containing 2% FBS was added to each well so as to incubate the cells in 0.5% serum for 12–16 h. Cells were pretreated with 10 μm SB203580 or 30 μm PD98059 or with the equivalent amount of solvent (Me2SO) as a control for 45 min prior to stimulation with hGH. 50 nm hGH was added for an additional 5–7 h. The cells were washed in PBS and lysed with 300 μl of 1× lysis buffer (25 mm Tris phosphate, pH 7.8, 2 mm EDTA, 2 mm dithiothreitol, 10% glycerol, 1% Triton X-100) by a freeze-thaw cycle, and lysate was collected by centrifugation at 14,000 rpm for 15 min. The supernatant was used for the assay of luciferase and β-galactosidase activity. The luciferase activities were normalized on the basis of protein content as well as on the β-galactosidase activity of pCMVβ vector. The β-galactosidase assay was performed with 20 μl of precleared cell lysate according to a standard protocol (62.Sambrook J. Fritsch E.F. Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY1989Google Scholar). Mean and standard deviations of at least three independent experiments are shown in the figures. Cells were fixed in ice-cold 4% paraformaldehyde, washed with PBS, permeabilized for 5 min with 0.1% Triton X-100, blocked in 2% bovine serum albumin, and incubated with phalloidin-TRITC (0.2 mg/ml) after the indicated treatments. Excess phalloidin-TRITC was removed by extensive washing with PBS. Labeled cells were visualized with a Carl Zeiss Axioplan microscope equipped with epifluorescence optics and a Bio-Rad MRC1024 confocal laser system. Images were converted to the tagged information file format and processed with the MacIntosh Photoshop program. Cell proliferation was assayed by measuring incorporation of [3H]thymidine during DNA synthesis (63.Coward P. Wada H.G. Falk M.S. Chan S.D. Meng F. Akil H. Conklin B.R. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 352-357Crossref PubMed Scopus (206) Google Scholar). Subconfluent CHO-GHR1–638 cell monolayers in 24-well plates were grown to quiescence in serum-free Ham's F-12 medium at